📊 VOR Key Takeaways
Is Vor Biopharma Inc. (VOR) a Good Investment?
Vor Biopharma is a pre-revenue biotech company with negative stockholders' equity of -$164.3M and annual cash burn of ~$143.7M, limiting runway to approximately 2.7 years. The deteriorating financial trajectory (diluted EPS worsened 107.2% YoY), mounting operating losses of -$371.6M, and balance sheet insolvency present fundamental risk despite a $396.5M cash buffer.
Why Buy Vor Biopharma Inc. Stock? VOR Key Strengths
- Strong cash position of $396.5M provides interim runway for clinical development activities
- Excellent liquidity ratios (18.20x current ratio) ensure ability to meet short-term obligations
- Biotech sector exposure with potential for substantial value creation if pipeline achieves regulatory approval and commercialization
VOR Stock Risks: Vor Biopharma Inc. Investment Risks
- Negative stockholders' equity of -$164.3M indicates balance sheet insolvency and liabilities exceeding assets
- Annual cash burn of ~$143.7M limits capitalization runway to approximately 2.7 years without additional funding or partnerships
- Pre-revenue stage with no commercial validation; dependent on successful clinical trials, regulatory approval, and market adoption with deteriorating metrics (EPS decline of 107.2% YoY)
Key Metrics to Watch
- Clinical trial progression and regulatory milestone achievements for lead candidates
- Quarterly cash burn rate and potential extension through capital raises or strategic partnerships
- Path to revenue through licensing agreements, partnering deals, or product approvals
Vor Biopharma Inc. (VOR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 18.20x current ratio provides a solid financial cushion.
VOR Profit Margin, ROE & Profitability Analysis
VOR vs Healthcare Sector: How Vor Biopharma Inc. Compares
How Vor Biopharma Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vor Biopharma Inc. Stock Overvalued? VOR Valuation Analysis 2026
Based on fundamental analysis, Vor Biopharma Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vor Biopharma Inc. Balance Sheet: VOR Debt, Cash & Liquidity
VOR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vor Biopharma Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-34.03 indicates the company is currently unprofitable.
VOR Revenue Growth, EPS Growth & YoY Performance
Vor Biopharma Inc. Dividends, Buybacks & Capital Allocation
VOR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vor Biopharma Inc. (CIK: 0001817229)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VOR
What is the AI rating for VOR?
Vor Biopharma Inc. (VOR) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VOR's key strengths?
Claude: Strong cash position of $396.5M provides interim runway for clinical development activities. Excellent liquidity ratios (18.20x current ratio) ensure ability to meet short-term obligations.
What are the risks of investing in VOR?
Claude: Negative stockholders' equity of -$164.3M indicates balance sheet insolvency and liabilities exceeding assets. Annual cash burn of ~$143.7M limits capitalization runway to approximately 2.7 years without additional funding or partnerships.
What is VOR's revenue and growth?
Vor Biopharma Inc. reported revenue of N/A.
Does VOR pay dividends?
Vor Biopharma Inc. does not currently pay dividends.
Where can I find VOR SEC filings?
Official SEC filings for Vor Biopharma Inc. (CIK: 0001817229) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VOR's EPS?
Vor Biopharma Inc. has a diluted EPS of $-70.50.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VOR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Vor Biopharma Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VOR stock overvalued or undervalued?
Valuation metrics for VOR: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VOR stock in 2026?
Our dual AI analysis gives Vor Biopharma Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VOR's free cash flow?
Vor Biopharma Inc.'s operating cash flow is $-142.7M, with capital expenditures of $941.0K.
How does VOR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 18.20 (avg: 2).